RecruitingPhase 1NCT06433947
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Studying Plasma cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Opna Bio LLC
- Intervention
- OPN-6602(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (11)
- Banner MD Anderson, Gilbert, Arizona, United States
- Stanford Cancer Institute, Stanford, California, United States
- Emory Winchip Cancer Center, Atlanta, Georgia, United States
- University of Kansas Clinical Research Center, Westwood, Kansas, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- START Midwest, Grand Rapids, Michigan, United States
- University of Rochester Medical Center, Rochester, New York, United States
- University of North Carolina Hospitals at Hillsborough, Chapel Hill, North Carolina, United States
- Huntsman Cancer Center Institute University of Utah, Salt Lake City, Utah, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06433947 on ClinicalTrials.govOther trials for Plasma cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07446777FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseUniversity of Miami
- RECRUITINGPHASE1NCT07333261Study of BMS-986453 in Newly Diagnosed Multiple MyelomaSusan Bal
- RECRUITINGPHASE3NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC
- RECRUITINGPHASE1NCT07093554Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaMedical College of Wisconsin
- RECRUITINGPHASE2NCT06920251Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapySeoul National University Hospital
- RECRUITINGPHASE2NCT06822972HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMDuke University
- RECRUITINGNANCT07045727Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaMayo Clinic
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07210047Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsHuniLife Biotechnology, Inc.